These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1085 related items for PubMed ID: 16563469

  • 1. Monitoring platelet inhibition after clopidogrel with the VerifyNow-P2Y12(R) rapid analyzer: the VERIfy Thrombosis risk ASsessment (VERITAS) study.
    Malinin A, Pokov A, Spergling M, Defranco A, Schwartz K, Schwartz D, Mahmud E, Atar D, Serebruany V.
    Thromb Res; 2007; 119(3):277-84. PubMed ID: 16563469
    [Abstract] [Full Text] [Related]

  • 2. The use of the VerifyNow P2Y12 point-of-care device to monitor platelet function across a range of P2Y12 inhibition levels following prasugrel and clopidogrel administration.
    Jakubowski JA, Payne CD, Li YG, Brandt JT, Small DS, Farid NA, Salazar DE, Winters KJ.
    Thromb Haemost; 2008 Feb; 99(2):409-15. PubMed ID: 18278193
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Assessment of platelet response to clopidogrel with multiple electrode aggregometry, the VerifyNow P2Y12 analyzer and platelet Vasodilator-Stimulated Phosphoprotein flow cytometry.
    von Beckerath N, Sibbing D, Jawansky S, Braun S, Morath T, Vogt W, Schömig A, Kastrati A.
    Blood Coagul Fibrinolysis; 2010 Jan; 21(1):46-52. PubMed ID: 19823079
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Differential sensitivity and kinetics of response of different ex vivo tests monitoring functional variability of platelet response to clopidogrel.
    Bal Dit Sollier C, Berge N, Boval B, Dubar M, Drouet L.
    Thromb Haemost; 2010 Sep; 104(3):571-81. PubMed ID: 20664906
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study.
    Angiolillo DJ, Shoemaker SB, Desai B, Yuan H, Charlton RK, Bernardo E, Zenni MM, Guzman LA, Bass TA, Costa MA.
    Circulation; 2007 Feb 13; 115(6):708-16. PubMed ID: 17261652
    [Abstract] [Full Text] [Related]

  • 10. The influencing factors for clopidogrel-mediated platelet inhibition are assay-dependent.
    Gremmel T, Steiner S, Seidinger D, Koppensteiner R, Panzer S, Kopp CW.
    Thromb Res; 2011 Oct 13; 128(4):352-7. PubMed ID: 21621250
    [Abstract] [Full Text] [Related]

  • 11. Role of the T744C polymorphism of the P2Y12 gene on platelet response to a 600-mg loading dose of clopidogrel in 597 patients with non-ST-segment elevation acute coronary syndrome.
    Cuisset T, Frere C, Quilici J, Morange PE, Saut N, Lambert M, Camoin L, Vague IJ, Bonnet JL, Alessi MC.
    Thromb Res; 2007 Oct 13; 120(6):893-9. PubMed ID: 17337040
    [Abstract] [Full Text] [Related]

  • 12. Usefulness of platelet response to clopidogrel by point-of-care testing to predict bleeding outcomes in patients undergoing percutaneous coronary intervention (from the Antiplatelet Therapy for Reduction of Myocardial Damage During Angioplasty-Bleeding Study).
    Patti G, Pasceri V, Vizzi V, Ricottini E, Di Sciascio G.
    Am J Cardiol; 2011 Apr 01; 107(7):995-1000. PubMed ID: 21256470
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. VerifyNow and VASP phosphorylation assays give similar results for patients receiving clopidogrel, but they do not always correlate with platelet aggregation.
    Bidet A, Jais C, Puymirat E, Coste P, Nurden A, Jakubowski J, Nurden P.
    Platelets; 2010 Apr 01; 21(2):94-100. PubMed ID: 20148735
    [Abstract] [Full Text] [Related]

  • 15. How to optimise clopidogrel therapy? Reducing the low-response incidence by aggregometry-guided therapy modification.
    Neubauer H, Lask S, Engelhardt A, Mügge A.
    Thromb Haemost; 2008 Feb 01; 99(2):357-62. PubMed ID: 18278186
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Antiplatelet effect of clopidogrel in patients with aspirin therapy undergoing percutaneous coronary interventions--limited inhibition of the P2Y12 receptor.
    Lepäntalo A, Virtanen KS, Reséndiz JC, Mikkelsson J, Viiri LE, Karhunen PJ, Lassila R.
    Thromb Res; 2009 Jun 01; 124(2):193-8. PubMed ID: 19232433
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Common sequence variations in the P2Y12 and CYP3A5 genes do not explain the variability in the inhibitory effects of clopidogrel therapy.
    Smith SM, Judge HM, Peters G, Armstrong M, Fontana P, Gaussem P, Daly ME, Storey RF.
    Platelets; 2006 Jun 01; 17(4):250-8. PubMed ID: 16769602
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 55.